MX2015006998A - Una composicion acuosa estable que comprende insulina humana o un analogo o derivado de la misma. - Google Patents

Una composicion acuosa estable que comprende insulina humana o un analogo o derivado de la misma.

Info

Publication number
MX2015006998A
MX2015006998A MX2015006998A MX2015006998A MX2015006998A MX 2015006998 A MX2015006998 A MX 2015006998A MX 2015006998 A MX2015006998 A MX 2015006998A MX 2015006998 A MX2015006998 A MX 2015006998A MX 2015006998 A MX2015006998 A MX 2015006998A
Authority
MX
Mexico
Prior art keywords
human insulin
stable aqueous
analogue
derivative
aqueous composition
Prior art date
Application number
MX2015006998A
Other languages
English (en)
Other versions
MX360420B (es
Inventor
Maharaj K Sahib
Jeetendra Kashinath Ambulge
Gauravkumar Ramanlal Agrawal
Original Assignee
Wockhardt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wockhardt Ltd filed Critical Wockhardt Ltd
Publication of MX2015006998A publication Critical patent/MX2015006998A/es
Publication of MX360420B publication Critical patent/MX360420B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Una preparación de insulina acuosa estable que comprende insulina humana, análogos o derivados de la misma, uno o más agentes potenciadores de solubilidad son seleccionados de urea, amino ácidos y/o surfactantes opcionalmente uno o más de los excipientes farmacéuticamente aceptables.
MX2015006998A 2012-12-19 2013-05-24 Una composicion acuosa estable que comprende insulina humana o un analogo o derivado de la misma. MX360420B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN3563MU2012 2012-12-19
PCT/IB2013/054286 WO2014096985A2 (en) 2012-12-19 2013-05-24 A stable aqueous composition comprising human insulin or an analogue or derivative thereof

Publications (2)

Publication Number Publication Date
MX2015006998A true MX2015006998A (es) 2015-09-23
MX360420B MX360420B (es) 2018-10-31

Family

ID=54141060

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015006998A MX360420B (es) 2012-12-19 2013-05-24 Una composicion acuosa estable que comprende insulina humana o un analogo o derivado de la misma.

Country Status (11)

Country Link
US (1) US9707275B2 (es)
JP (1) JP6111475B2 (es)
CN (1) CN104994864B (es)
AU (1) AU2013365945B2 (es)
BR (1) BR112015011179A8 (es)
CA (1) CA2889165A1 (es)
MX (1) MX360420B (es)
NZ (1) NZ707160A (es)
RU (1) RU2015129087A (es)
WO (1) WO2014096985A2 (es)
ZA (1) ZA201502988B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2760261T3 (es) 2014-02-13 2020-05-13 Incyte Corp Ciclopropilaminas como inhibidores de LSD1
HUE045725T2 (hu) 2014-02-13 2020-01-28 Incyte Corp Ciklopropilaminok mint LSD1 inhibitorok
WO2016007722A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
MX2017012699A (es) 2015-04-03 2018-02-09 Incyte Corp Compuestos heterociclicos como inhibidores de demetilasa 1 especifica de lisina (lsd1).
KR20180051523A (ko) 2015-08-12 2018-05-16 인사이트 코포레이션 Lsd1 저해제의 염
EP3419649A1 (en) * 2016-02-25 2019-01-02 Wockhardt Limited Pharmaceutical composition of insulin glargine and amino acids
GB201607918D0 (en) 2016-05-06 2016-06-22 Arecor Ltd Novel formulations
GB201613896D0 (en) * 2016-08-12 2016-09-28 Arecor Ltd Novel composition
GB201613895D0 (en) 2016-08-12 2016-09-28 Arecor Ltd Novel composition
EP3518893A1 (en) * 2016-09-29 2019-08-07 Arecor Limited Novel formulations
GB201707189D0 (en) * 2017-05-05 2017-06-21 Arecor Ltd Novel formulations
SG11202005322RA (en) * 2017-12-07 2020-07-29 Adocia Injectable solution at ph 7 comprising at least one basal insulin having a pi of between 5.8 and 8.5 and a copolyamino acid carrying carboxylate charges and hydrophobic radicals
CN108096185A (zh) * 2017-12-20 2018-06-01 珠海冀百康生物科技有限公司 一种速效胰岛素制剂及其制备方法
CN108114270B (zh) * 2018-02-06 2019-08-20 美药星（南京）制药有限公司 一种门冬胰岛素注射液的制备方法
CN112040928A (zh) * 2018-04-04 2020-12-04 艾瑞克有限公司 用于递送胰岛素化合物的医用输注泵系统
WO2020047198A1 (en) 2018-08-31 2020-03-05 Incyte Corporation Salts of an lsd1 inhibitor and processes for preparing the same
CN111912838B (zh) * 2020-06-24 2023-05-12 宁波瑞源生物科技有限公司 一种bnp化学发光检测试剂盒及其应用

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4371523A (en) * 1980-12-29 1983-02-01 The Regents Of The University Of California Reducing the aggregation of insulin in solution
FI78616C (fi) * 1982-02-05 1989-09-11 Novo Industri As Foerfarande foer framstaellning av en foer infusionsaendamaol avsedd stabiliserad insulinloesning, som har en foerhoejd zinkhalt.
DE3316363A1 (de) 1983-05-05 1984-11-08 Deutsche Babcock Anlagen Ag, 4200 Oberhausen Walzenrost fuer muellverbrennungsanlagen
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
AU609769B2 (en) * 1987-02-10 1991-05-09 Drug Delivery Systems Inc. Electrolytic transdermal delivery of proteins
DK257988D0 (da) 1988-05-11 1988-05-11 Novo Industri As Nye peptider
DE3837825A1 (de) * 1988-11-08 1990-05-10 Hoechst Ag Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
JPH04502465A (ja) 1988-12-23 1992-05-07 ノボ　ノルディスク　アクティーゼルスカブ ヒトインシュリン類似物質
PT93057B (pt) 1989-02-09 1995-12-29 Lilly Co Eli Processo para a preparacao de analogos da insulina
US5126249A (en) * 1989-05-09 1992-06-30 Eli Lilly And Company Enzymatic removal of a protein amino-terminal sequence
DK155690D0 (da) 1990-06-28 1990-06-28 Novo Nordisk As Nye peptider
US5474978A (en) 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
US5866538A (en) 1996-06-20 1999-02-02 Novo Nordisk A/S Insulin preparations containing NaCl
US5948751A (en) 1996-06-20 1999-09-07 Novo Nordisk A/S X14-mannitol
AR012894A1 (es) 1997-06-13 2000-11-22 Lilly Co Eli Formulacion de insulina en solucion estable, su uso para preparar un medicamento y proceso para la preparacion de la misma.
US6531448B1 (en) * 1997-12-23 2003-03-11 Eli Lilly And Company Insoluble compositions for controlling blood glucose
ATE290877T1 (de) 1998-01-09 2005-04-15 Novo Nordisk As Stabilisierte insulin-zubereitungen
MXPA01013168A (es) 1999-06-30 2002-07-30 Inhale Therapeutic Syst Proceso de secado por rocio para preparar polvos secos.
US6734162B2 (en) 2000-01-24 2004-05-11 Minimed Inc. Mixed buffer system for stabilizing polypeptide formulations
US6737401B2 (en) 2001-06-28 2004-05-18 Metronic Minimed, Inc. Methods of evaluating protein formulation stability and surfactant-stabilized insulin formulations derived therefrom
DE10227232A1 (de) * 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Saure Insulinzubereitungen mit verbesserter Stabilität
JP4147235B2 (ja) * 2004-09-27 2008-09-10 キヤノン株式会社 吐出用液体、吐出方法、液滴化方法、液体吐出カートリッジ及び吐出装置
WO2006053906A1 (en) 2004-11-22 2006-05-26 Novo Nordisk A/S Soluble, stable insulin-containing formulations with a protamine salt
JP5235661B2 (ja) 2005-05-25 2013-07-10 ノボ・ノルデイスク・エー／エス 安定化ポリペプチド製剤
WO2007041481A1 (en) 2005-09-29 2007-04-12 Biodel, Inc. Rapid acting and prolonged acting insulin preparations
US7713929B2 (en) * 2006-04-12 2010-05-11 Biodel Inc. Rapid acting and long acting insulin combination formulations
CN101045158A (zh) 2006-03-31 2007-10-03 北京大学 胰岛素类似物干粉组合物及其制备方法
US20090325860A1 (en) 2006-08-04 2009-12-31 Nastech Pharmaceutical Company Inc. Compositions for intranasal delivery of human insulin and uses thereof
US9034818B2 (en) * 2007-06-13 2015-05-19 Novo Nordisk A/S Pharmaceutical formulations comprising an insulin derivative
CN101951957A (zh) 2008-01-04 2011-01-19 百达尔公司 胰岛素释放作为组织的葡萄糖水平的函数的胰岛素制剂
TWI394580B (zh) * 2008-04-28 2013-05-01 Halozyme Inc 超快起作用胰島素組成物
WO2009133529A2 (en) * 2008-04-30 2009-11-05 Wockhardt Research Centre Processes for refolding of insulin
WO2010028055A1 (en) 2008-09-02 2010-03-11 Biodel, Inc. Insulin with a basal release profile
US20100203014A1 (en) 2009-02-04 2010-08-12 Aegis Therapeutics Llc Zwitterionic buffered acidic peptide and protein formulations
CN102470165B (zh) 2009-06-26 2014-12-24 诺沃-诺迪斯克有限公司 包含胰岛素、烟酰胺和氨基酸的制剂
MA33442B1 (fr) 2009-07-06 2012-07-03 Sanofi Aventis Deutschland Préparations d'insuline contenant de la méthionine
AU2011202239C1 (en) * 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins
WO2011156476A2 (en) * 2010-06-08 2011-12-15 Biodel Inc. Insulin with a basal release profile
WO2012066086A1 (en) 2010-11-17 2012-05-24 Sanofi-Aventis Deutschland Gmbh PHARMACEUTICAL FORMULATION COMPRISING INSULIN GLARGINE AND SULFOBUTYL ETHER 7-ß-CYCLODEXTRIN
WO2012115640A1 (en) * 2011-02-23 2012-08-30 Elona Biotechnologies Liquid insulin- containing compositions and methods of making the same
US20130011378A1 (en) 2011-06-17 2013-01-10 Tzung-Horng Yang Stable formulations of a hyaluronan-degrading enzyme
WO2013067022A1 (en) * 2011-10-31 2013-05-10 Xeris Pharmaceuticals, Inc. Formulations for the treatment of diabetes

Also Published As

Publication number Publication date
JP2016503784A (ja) 2016-02-08
JP6111475B2 (ja) 2017-04-12
BR112015011179A2 (pt) 2017-07-11
WO2014096985A2 (en) 2014-06-26
CN104994864B (zh) 2018-05-29
WO2014096985A3 (en) 2015-07-16
ZA201502988B (en) 2016-11-30
RU2015129087A (ru) 2017-02-02
AU2013365945A1 (en) 2015-05-07
US20150265683A1 (en) 2015-09-24
NZ707160A (en) 2016-08-26
US9707275B2 (en) 2017-07-18
CN104994864A (zh) 2015-10-21
AU2013365945B2 (en) 2017-03-02
CA2889165A1 (en) 2014-06-26
MX360420B (es) 2018-10-31
BR112015011179A8 (pt) 2019-10-01

Similar Documents

Publication Publication Date Title
NZ707160A (en) A stable aqueous composition comprising human insulin or an analogue or derivative thereof
MX2016006053A (es) Compuestos selectivos de peptido yy (pyy) y usos de los mismos.
AU2018256640A1 (en) Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
MX2016008979A (es) Formulaciones farmaceuticas estabilizadas de analogos de insulina y/o derivados de insulina.
MX2017015105A (es) Compuestos del peptido yy (pyy) selectivos y sus usos.
MX2019003693A (es) Formulaciones de insulina de accion prolongada.
MX2016008978A (es) Formulaciones farmaceuticas de analogos de insulina y/o derivados de insulina estabilizadas y que estan libres de glicerol.
MX369121B (es) Formulacion farmaceutica acuosa de tapentadol para administracion oral.
TR201900670T4 (tr) İnhalasyon için yöntem ve formülasyon.
PH12015502755A1 (en) Insulin glargine / lixisenatide fixed ratio formulation
MX348823B (es) Formulaciones estables de linaclotida.
IN2014MN01470A (es)
CY1118032T1 (el) Διεργασιες για την εμπορικη παρασκευη φαρμακευτικα δραστικου παραγοντα
PH12017501084A1 (en) Insulin glargine/lixisenatide fixed ratio formulation
MX2016005395A (es) Formulacion estable de insulina glulisina.
TW201613557A (en) Stable aqueous recombinant protein formulations
MY181181A (en) Fgf21 derivatives and uses thereof
WO2015023649A3 (en) Peptides for enhancing transdermal delivery
PH12015502082A1 (en) Improved stability and potency of hemagglutinin
WO2011002422A3 (en) Solubility enhancing pharmaceutical formulation
GB201014391D0 (en) Drug composition and its use in therapy
MX2021003908A (es) Polipeptidos de accion prolongada y metodos para su produccion y administracion.
MX2015006997A (es) Composicion farmaceutica.
WO2013032184A3 (ko) 피라지노-트리아진 유도체를 포함하는 조성물
BR112012023681A2 (pt) composição para administração nasal e método para prepará-la

Legal Events

Date Code Title Description
FG Grant or registration